Veru mulls selling female health business
Veru Adds Financial Advisor to Pursue Alternatives for Female Health Business
Veru Will Explore Strategic Alternatives For Its Legacy Female Health Unit
BRIEF-Veru Receives FDA Agreement To Advance Veru-111 Into Phase 3 Study In Hospitalized Covid-19 Patients At High Risk For Acu
Veru Gets FDA Approval to Move Covid-19 Treatment Into Phase 3 Study
Veru shares are trading higher after the company announced it received FDA agreement to advance VERU-111 into Phase 3 study in hospitalized COVID-19 patients at high risk for acute respiratory distres
Veru Price Target Cut to $21.00/Share From $22.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Veru, Lowers Price Target to $21
Veru analyst ratings
Veru Files US Application For TADFIN Combo For Prostate Enlargement
